In fact, in the study conducted by Nakamura T et al. in 2017, elevated pretreatment CRP levels were found in 43.5% of metastatic STS patients [21], higher than their previous studies where only 18 to 22% of the non-metastatic STS patients had elevated pretreatment CRP levels [15]. The gene discussed is CRP; the disease is telomere syndrome.